Cardiovascular safety and hemodynamic considerations in oncology drug development – webinar highlights October 10th 2012

Author： Braddock Martin Heilbraun Jeff Mendzelevski Boaz

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.5, 2013-09, pp. : 783-791

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacology: Special Safety Considerations in Drug Development and Pharmacovigilance

By Atuah K.N. Hughes D. Pirmohamed M.

Drug Safety, Vol. 27, Iss. 8, 2004-01 ,pp. : 535-554

Adis International

Access to resources Recommend Favorite

Report on the 10th Anniversary of International Drug Discovery Science and Technology Conference, 8 – 10 November 2012, Nanjing, China

By Everett Jeremy R

Expert Opinion on Drug Discovery, Vol. 8, Iss. 3, 2013-03 ,pp. : 357-361

Informa Healthcare

Access to resources Recommend Favorite

Drug safety communication: highlights from ISoP

Reactions Weekly, Vol. 1, Iss. 1374, 2011-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations

By Williams B.R.

Drugs & Aging, Vol. 20, Iss. 6, 2003-01 ,pp. : 445-463

Adis International

Access to resources Recommend Favorite

2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines

By Cavero Icilio

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 589-603

Informa Healthcare

Access to resources Recommend Favorite